Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

42 trials with published results (23%)

Research Maturity

121 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.5%

12 terminated out of 184 trials

Success Rate

91.0%

+4.5% vs benchmark

Late-Stage Pipeline

29%

53 trials in Phase 3/4

Results Transparency

35%

42 of 121 completed with results

Key Signals

42 with results91% success12 terminated

Data Visualizations

Phase Distribution

106Total
Not Applicable (20)
P 1 (10)
P 2 (23)
P 3 (28)
P 4 (25)

Trial Status

Completed121
Unknown28
Recruiting12
Terminated12
Withdrawn5
Active Not Recruiting3

Trial Success Rate

91.0%

Benchmark: 86.5%

Based on 121 completed trials

Clinical Trials (184)

Showing 20 of 20 trials
NCT06930625Phase 3RecruitingPrimary

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT05192382Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

NCT04261712Phase 2Active Not RecruitingPrimary

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

NCT07037420Phase 2RecruitingPrimary

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT00921609CompletedPrimary

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

NCT04837040Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

NCT07195175Phase 1RecruitingPrimary

Study of MAR002 in Healthy Men

NCT04125836Phase 3CompletedPrimary

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04066569Not ApplicableCompletedPrimary

Reproducibility and Utility of OGTT in Acromegaly

NCT05364944Phase 1TerminatedPrimary

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT07179926Recruiting

Effects of Pasireotide Lar Therapy on Bone Metabolism

NCT07100587Not ApplicableCompletedPrimary

Ketogenic vs. Mediterranean Diet on Metabolic and Hormonal Parameters in Patients With Active Acromegaly

NCT01809808CompletedPrimary

A Prospective Study of Outcome After Therapy for Acromegaly

NCT05964712RecruitingPrimary

Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study

NCT05131100RecruitingPrimary

Korean Regulatory Post Marketing Surveillance for Somavert

NCT06372652Phase 1CompletedPrimary

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

NCT03043586CompletedPrimary

Treatment Patterns and Treatment Outcomes for Acromegaly

NCT00461188RecruitingPrimary

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

NCT03792555Phase 2CompletedPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

NCT03789656Phase 2CompletedPrimary

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Scroll to load more

Research Network

Activity Timeline